NEKTAR THERAPEUTICS

NKTR· Nasdaq· Pharmaceutical Preparations

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
-377.8%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
-18.4%
We record prices for the companies we cover; NKTR is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
16.9M
Revenue
$55.2M
Free cash flow
-$208.7M
Owner earnings
-$221.3M

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
–
Operating
-253.7%
Net
-297.1%
Free cash flow
-377.8%
Owner earnings
-400.7%
Stock pay
22.9%

Returns

ROIC, FY2025
–
ROIC, 5 yr avg
–
ROE, FY2025
-182.6%
ROE, 5 yr avg
-153.4%

Growth (CAGR)

Revenue, 3 yr
-15.7%
Revenue, 5 yr
-18.4%
Revenue, 9 yr
-11.5%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Diluted EPS, 9 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–
Free cash flow, 9 yr
–

Financial health · FY2025

Cash and investments
$245.8M
Total debt
–
Net cash
–
Debt/Equity
–
Debt/FCF
–

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
7.2%

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$55.2M

-11.5% a year over 9 years

FY2016: Revenue $165.4MFY2017: Revenue $307.7MFY2018: Revenue $1.2BFY2019: Revenue $114.6MFY2020: Revenue $152.9MFY2021: Revenue $101.9MFY2022: Revenue $92.1MFY2023: Revenue $90.1MFY2024: Revenue $98.4MFY2025: Revenue $55.2M
FY2016FY2025

Margins

Operating-253.7%Net-297.1%

FY2025

FY2016: Operating -68.2%, Net -92.8%FY2017: Operating -19.4%, Net -31.4%FY2018: Operating 57.6%, Net 57.1%FY2019: Operating -383.9%, Net -384.5%FY2020: Operating -278.0%, Net -290.6%FY2021: Operating -437.8%, Net -514.0%FY2022: Operating -408.6%, Net -400.0%FY2023: Operating -292.6%, Net -306.3%FY2024: Operating -106.9%, Net -120.9%FY2025: Operating -253.7%, Net -297.1%
FY2016FY2025

Free cash flow and owner earnings

Free cash flow-$208.7MOwner earnings-$221.3M

FY2025

FY2016: Free cash flow -$123.4M, Owner earnings -$149.3MFY2017: Free cash flow -$90.1M, Owner earnings -$126.7MFY2018: Free cash flow $704.0M, Owner earnings $615.9MFY2019: Free cash flow -$355.0M, Owner earnings -$454.8MFY2020: Free cash flow -$320.5M, Owner earnings -$414.8MFY2021: Free cash flow -$427.6M, Owner earnings -$522.3MFY2022: Free cash flow -$309.7M, Owner earnings -$367.0MFY2023: Free cash flow -$193.5M, Owner earnings -$226.9MFY2024: Free cash flow -$177.2M, Owner earnings -$198.8MFY2025: Free cash flow -$208.7M, Owner earnings -$221.3M
FY2016FY2025

Diluted shares

16.9M

+81.3% over 9 years, net dilution

FY2016: Diluted shares 9.3MFY2017: Diluted shares 10.4MFY2018: Diluted shares 12.0MFY2019: Diluted shares 11.7MFY2020: Diluted shares 11.9MFY2021: Diluted shares 12.2MFY2022: Diluted shares 12.5MFY2023: Diluted shares 12.7MFY2024: Diluted shares 13.7MFY2025: Diluted shares 16.9M
FY2016FY2025

Every figure, year by year

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
The business
Revenue$165.4M$307.7M$1.2B$114.6M$152.9M$101.9M$92.1M$90.1M$98.4M$55.2M
Revenue growth-28.3%86.0%287.8%-90.4%33.4%-33.4%-9.7%-2.1%9.2%-43.9%
Gross margin––––––––––
Operating margin-68.2%-19.4%57.6%-383.9%-278.0%-437.8%-408.6%-292.6%-106.9%-253.7%
Net income-$153.5M-$96.7M$681.3M-$440.7M-$444.4M-$523.8M-$368.2M-$276.1M-$119.0M-$164.1M
Net margin-92.8%-31.4%57.1%-384.5%-290.6%-514.0%-400.0%-306.3%-120.9%-297.1%
Diluted EPS$-16.50s$-9.30s$56.70s$-37.80s$-37.35s$-42.90s$-29.55s$-21.75s$-8.68$-9.73
Return on invested capital?––––––––––
Cash
Operating cash flow-$117.0M-$80.4M$718.2M-$328.7M-$313.3M-$412.7M-$304.0M-$192.6M-$175.7M-$208.5M
Capital expenditure$6.4M$9.7M$14.2M$26.3M$7.3M$15.0M$5.7M$865.0K$1.5M$171.0K
Free cash flow-$123.4M-$90.1M$704.0M-$355.0M-$320.5M-$427.6M-$309.7M-$193.5M-$177.2M-$208.7M
Stock-based compensation$25.9M$36.6M$88.1M$99.8M$94.3M$94.7M$57.3M$33.4M$21.6M$12.6M
Owner earnings?-$149.3M-$126.7M$615.9M-$454.8M-$414.8M-$522.3M-$367.0M-$226.9M-$198.8M-$221.3M
Free cash flow per share$-13.26$-8.67$58.63$-30.43$-26.92$-35.00$-24.82$-15.27$-12.92$-12.37
Capital allocation
Dividends paid––––––––––
Share repurchases–––––––$0$3.0M$0
Diluted shares9.3Ms10.4Ms12.0Ms11.7Ms11.9Ms12.2Ms12.5Ms12.7Ms13.7M16.9M
Share count change?–11.7%15.5%-2.8%2.1%2.6%2.1%1.5%8.2%23.0%
Balance sheet
Cash and equivalents$59.6M$4.8M$194.9M$96.4M$199.0M$25.2M$88.2M$35.3M$44.3M$15.1M
Short-term investments–$291.4M$1.1B$1.2B$862.9M$708.7M$416.8M$268.3M$211.0M$230.6M
Total debt––––––––––
Net debt––––––––––
Shareholders' equity$88.1M$87.8M$1.7B$1.4B$1.1B$679.5M$366.6M$131.0M$60.7M$89.8M

Latest filings

All on EDGAR
2026-08-1410-QQuarterly report
2026-08-138-KEarnings release
2026-05-0810-QQuarterly report
2026-05-078-KEarnings release
2026-04-24DEF 14AProxy statement
2026-03-1310-KAnnual report
2026-03-128-KEarnings release
2025-11-0710-QQuarterly report
2025-11-068-KEarnings release
2025-08-0810-QQuarterly report

More from our coverage

All coverage